Cipla is currently trading at Rs. 548.70, up by 0.15 points or 0.03% from its previous closing of Rs. 548.55 on the BSE.
The scrip opened at Rs. 551.40 and has touched a high and low of Rs. 551.40 and Rs. 548.00 respectively. So far 2019 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 678.00 on 19-Sep-2018 and a 52 week low of Rs. 483.75 on 29-Jan-2019.
Last one week high and low of the scrip stood at Rs. 557.95 and Rs. 545.00 respectively. The current market cap of the company is Rs. 44196.62 crore.
The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.60% and 23.69% respectively.
Cipla and its subsidiary Cipla USA, Inc., will launch a phase of generic Cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) in the USA. The launch is a subject of ongoing litigation. The company's cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) is AB-rated generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen, Inc.
Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1502.30 |
| Dr. Reddys Lab | 6198.90 |
| Cipla | 1402.20 |
| Zydus Lifesciences | 957.00 |
| Lupin | 1645.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
